微轴流泵与耐久性左心室辅助装置桥接心脏移植的结局比较
单中心回顾性队列研究比较2019年5月至2024年5月间以微轴流泵(ma-LVAD)与耐久性左心室辅助装置(d-LVAD)桥接至原位心脏移植患者的特征与结局。结果显示两组生存无差异,但d-LVAD组术后输血量、中重度原发性移植物功能障碍、延迟胸骨闭合、首次活检排斥反应及ICU和总住院时间均更高。
要点
- ma-LVAD桥接与d-LVAD桥接相比,心脏移植后生存无差异。
- d-LVAD桥接者术后输血量、中重度原发性移植物功能障碍和延迟胸骨闭合更多。
- d-LVAD组首次术后活检排斥比例更高,ICU和总住院时间更长。
核心结论
- ma-LVAD与d-LVAD作为桥接策略相比,生存无差异,但ma-LVAD桥接与心脏移植后更低并发症相关。
研究设计与样本
- 单中心回顾性队列研究,纳入2019年5月至2024年5月间接受原位心脏移植并以ma-LVAD或d-LVAD桥接的患者。
主要发现
- 研究期间ma-LVAD桥接比例从0%增至20%。
- 未校正Kaplan-Meier分析显示两种桥接策略生存无差异。
临床怎么用
- 对于需要桥接至心脏移植的患者,选择ma-LVAD可能降低移植后并发症,但需结合患者基线特征个体化决策。
局限性
- 单中心回顾性设计可能引入选择偏倚和混杂因素,未校正分析可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate characteristics and outcomes of patients bridged to orthotopic heart transplantation with microaxial left ventricular assist device (ma-LVAD) versus durable LVAD (d-LVAD). METHODS: This was a single-center retrospective cohort study in which characteristics outcomes of patients undergoing orthotopic heart transplantation between May 2019 and May 2024 who were bridged with ma-LVAD versus d-LVAD, were compared. RESULTS: Over the study period, the percentage of patients bridged with ma-LVAD increased from 0% to 20%. Patients bridged with d-LVAD were more likely to have history of hypertension (80% vs 65%; P = .03), a higher body mass index (32.53 vs 28.15; P < .0001), and anti-human leukocyte antigens antibodies (54% vs 36%; P = .02) before transplant, otherwise groups were similar in their baseline characteristics. Unadjusted Kaplan-Meier analysis demonstrated no difference in survival between these 2 bridging strategies. However, postoperative blood product use (3 vs 0 units; P < .0001), moderate or severe primary graft dysfunction (27% vs 14%; P = .04), and delayed sternal closure (45% vs 9%; P < .0001) were all higher among those bridged with d-LVAD versus ma-LVAD. Rejection on the first postoperative biopsy was reported in a 60% in the d-LVAD group versus 33% in the ma-LVAD group (P = .0006). Postoperative intensive care unit (7 vs 6 days; P = .03) and overall postoperative length of stay (17 vs 12 days; P = .002) were greater in patients bridged with d-LVAD versus ma-LVAD, respectively. CONCLUSIONS: The use of ma-LVAD compared with d-LVAD as a bridging strategy was not associated with differences in survival. However, bridging with ma-LVAD compared with d-LVAD was associated with lower morbidity after orthotopic heart transplantation.
引用
- Alvarez A, Dewan KC, Milano CA, et al. Outcomes among patients bridged to heart transplant with microaxial flow versus durable left ventricular assist device support. J Thorac Cardiovasc Surg. 2025. PMID: 41067676. doi:10.1016/j.jtcvs.2025.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。